Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: Ferroptosis and vascular arrest are present in the rat model of BPD induced by hyperoxia. A Comparison of body size and lung volume of rats after euthanasia; B Weight plot of rats in CON and BPD groups; C HE staining of rat lung tissue, scale bar: 50 μm; D Determination of mRNA contents of PTGS2, SLC7A11 and GPX4 in rat lung tissues, GAPDH was used as an internal control; E Quantitative analysis of radial alveolar count in rat lung tissues by HE staining; F - G . Protein expression and gray value quantitative analysis of PTGS2, SLC7A11 and GPX4 in lung tissue of rats, GAPDH was used as a whole protein internal control; The levels of LPO, MDA, SOD and GSH in serum of ( H - K ). L Determination of VEGFA and CD31 mRNA content in rat lung tissue, GAPDH was used as internal control; Protein expression and gray value quantification of VEGFA and CD31 in lung tissues of ( M - N ). GAPDH was used as a whole protein internal control. N = 6, p < 0.05 for statistically significant (* p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Comparison, Staining, Control, Expressing

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: Effect of SLC7A11 knockdown on SP intervention. A - C SLC7A11 siRNA knockdown efficiency was detected by RT-qPCR and Western blot; D - E PTGS2, CD31 and VEGFA protein detection and gray value quantification of HUVECs, GAPDH was used as an internal control; F - H , J Fluorescence plots and quantification of LPO and ROS of HUVECs, scale scale =100 μm, This fluorescent probe can emit red fluorescence under normal circumstances, and the fluorescence will change from red to green as lipid peroxidation occurs. The formation of lipid peroxides can be detected with high sensitivity through the fluorescence intensities of red and green.; I GSH measurement of HUVEC. Two-sided unpaired t test was used for comparison between the two groups. N =6, p <0.05 was considered statistically significant (* p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001, ns: no difference)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Knockdown, Quantitative RT-PCR, Western Blot, Control, Fluorescence, Comparison

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: Effect of GPX4 knockdown on SP intervention. A - C GPX4 siRNA knockdown efficiency was detected by RT-PCR and western blot; D - E PTGS2, CD31 and VEGFA protein detection and gray value quantification of HUVECs, GAPDH was used as an internal control; F - H , J Fluorescence plots and quantification of LPO and ROS of HUVEC, scale scale =100 μm, This fluorescent probe can emit red fluorescence under normal circumstances, and the fluorescence will change from red to green as lipid peroxidation occurs. The formation of lipid peroxides can be detected with high sensitivity through the fluorescence intensities of red and green.; I GSH measurement of HUVECs. Two-sided unpaired t test was used for comparison between the two groups. N =6, p <0.05 was considered statistically significant (* p <0.05, ** p <0.01, *** p <0.001, ns: no difference)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Knockdown, Reverse Transcription Polymerase Chain Reaction, Western Blot, Control, Fluorescence, Comparison

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: A proposed mechanistic model illustrating how SP alleviates BPD. In HUVECs, hyperoxia exposure suppresses the SLC7A11/GPX4 antioxidant axis, leading to increased lipid peroxidation (LPO) and reactive oxygen species (ROS), thereby triggering ferroptosis. Concurrently, the expression of pro-angiogenic factors (VEGFA, CD31) is downregulated, resulting in impaired vascular development and alveolar simplification—the hallmark pathological features of BPD. SP treatment counteracts hyperoxia-induced damage by upregulating the SLC7A11/GPX4 pathway. The activation of this axis inhibits ferroptosis (reducing LPO and ROS) and restores the expression of VEGFA and CD31, thereby promoting angiogenesis and preserving alveolar structure. This model summarizes the core finding: SP exerts protective effects against BPD by modulating ferroptosis and vascular development through the SLC7A11/GPX4 signaling axis

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Expressing, Activation Assay, Preserving

Journal: Archives of Medical Science : AMS

Article Title: Therapeutic potential of mesenchymal stem cells in cisplatin-induced acute kidney injury via ASK-1/TXNIP pathway modulation

doi: 10.5114/aoms/193707

Figure Lengend Snippet: Immunohistochemical staining of VEGF of renal cortex sections at magnification ×400, bar 25 µm. A – Immunohistochemical-stained kidney sections of control group showing strong reaction of VEGF protein expression in the renal cortex. B – Immunohistochemical-stained kidney sections of AKI group showing significant reduction in the expression of VEGF in renal medulla. C – Immunohistochemical-stained kidney sections for VEGF protein expression of FUR group showing mild increase in the expression of VEGF in renal cortex. D – Immunohistochemical-stained kidney sections for VEGF protein expression of MSCs group showing marked increase in the expression of VEGF in renal medulla E – The angiogenic effects of MSC in kidney tissue, expressed as area %. Data were presented as means ± SEM. Each column represented the means ± SEM. The mean variations between the groups using Turkey’s significant difference test. a p < 0.01 vs. control, b p < 0.01 vs. cisplatin induced acute kidney injury cells, c p < 0.01 vs. furosemide treated cells

Article Snippet: Hematoxylin and eosin (H&E) stain was applied to 5 μm sections of paraffin-embedded renal tissues for histological investigation [ ], using anti-VEGF rabbit polyclonal Ab (Boster Biological Technology, Pleasanton, CA, USA, Cat.# PA1080).

Techniques: Immunohistochemical staining, Staining, Control, Expressing

Journal: Stem Cell Research & Therapy

Article Title: Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling

doi: 10.1186/s13287-026-04929-2

Figure Lengend Snippet: Assessment of the tube formation capability, CD31 and VEGF gene expressions for HUVECs treated without (control) and with cell culture supernatant collected from H-EMSCs seeded on PCL-HA (PCL-HA/H-E) or H-EMSCs and mø co-seeded on PCL-HA (PCL-HA/H-E/mø). A Tube formation assay of HUVECs in the control, PCL-HA/H-E and PCL-HA/H-E/mø groups. Scale bar = 200 μm. B Quantification of the total length of the tubes formed. C Quantification of the total number of meshes formed. D Quantification of the number of nodes formed. E CD31 gene expression of the HUVECs. F VEGF gene expression of the HUVECs. *** p < 0.001. ## p < 0.01, ### p < 0.001 vs. Control

Article Snippet: The following lists the primary and secondary antibodies used: rabbit polyclonal to CD31 (1:200, 28083-1-AP, Proteintech); rabbit polyclonal to VEGF (1:200, PB9071, Boster); AlexaFluor ® 488 goat anti-mouse IgG (1:200, A28175, Thermo scientific) and AlexaFluor ® 568 goat anti-rabbit IgG (1:200, A-11011, Thermo scientific).

Techniques: Control, Cell Culture, Tube Formation Assay, Gene Expression

Journal: Stem Cell Research & Therapy

Article Title: Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling

doi: 10.1186/s13287-026-04929-2

Figure Lengend Snippet: Assessment of the tube formation capability, CD31 and VEGF gene expressions of HUVECs treated with cell culture supernatant collected from H-EMSCs seeded on PCL-HA (PCL-HA/H-E) or H-EMSCs and mø co-seeded on PCL-HA (PCL-HA/H-E/mø) or H-EMSCs and mø co-seeded on PCL-HA and VEGF inhibitor (PCL-HA/H-E/mø/VEGF inhibitor). A Tube formation assay of HUVECs in the PCL-HA/H-E, PCL-HA/H-E/mø and PCL-HA/H-E/mø/VEGF inhibitor groups. Scale bar = 200 μm. B Quantification of the total length of the tubes formed. C Quantification of the total number of meshes formed. D Quantification of the number of nodes formed. E CD31 gene expression of the HUVECs. F VEGF gene expression of the HUVECs. *** p < 0.001. # p < 0.05, ### p < 0.001 vs. PCL-HA/H-E group

Article Snippet: The following lists the primary and secondary antibodies used: rabbit polyclonal to CD31 (1:200, 28083-1-AP, Proteintech); rabbit polyclonal to VEGF (1:200, PB9071, Boster); AlexaFluor ® 488 goat anti-mouse IgG (1:200, A28175, Thermo scientific) and AlexaFluor ® 568 goat anti-rabbit IgG (1:200, A-11011, Thermo scientific).

Techniques: Cell Culture, Tube Formation Assay, Gene Expression

Journal: Stem Cell Research & Therapy

Article Title: Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling

doi: 10.1186/s13287-026-04929-2

Figure Lengend Snippet: VEGF, CD31 gene and protein expression of rat endometrial tissues of the PCL-HA/H-E, PCL-HA/H-E/mø and PCL-HA/H-E/mø/VEGF inhibitor groups at day 7. A VEGF gene expression. B Quantification of VEGF protein concentration (pg/ml). C Representative images of VEGF immunostaining. Cell nuclei stained in blue while VEGF stained in red. Scale bar = 100 μm. D Quantification of VEGF staining area (%). E CD31 gene expression. F Representative images of CD31 immunostaining. Cell nuclei stained in blue while CD31 stained in red. Scale bar = 100 μm. G Quantification of CD31 staining area (%). *** p < 0.001. ## p < 0.01, ### p < 0.001 vs. PCL-HA/H-E group

Article Snippet: The following lists the primary and secondary antibodies used: rabbit polyclonal to CD31 (1:200, 28083-1-AP, Proteintech); rabbit polyclonal to VEGF (1:200, PB9071, Boster); AlexaFluor ® 488 goat anti-mouse IgG (1:200, A28175, Thermo scientific) and AlexaFluor ® 568 goat anti-rabbit IgG (1:200, A-11011, Thermo scientific).

Techniques: Expressing, Gene Expression, Protein Concentration, Immunostaining, Staining

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: M. suaveolens extract blocked the expression of VEGF and NF-κB mRNA in lung tissue. Groups of mice were challenged with cecal ligation and puncture and treated with M. suaveolens extract 24 h later. The left lung tissues were homogenized and total RNA was extracted using TRIzol reagent and assayed by quantitative polymerase chain reaction. (A) Representative gels assessing (a) VEGF and (b) NF-κB levels are demonstrated. Lane 1, marker; lane 2, normal control group; lane 3, sham operation group; lane 4, (untreated) sepsis group and lane 5, treatment group. (B) Statistical summary of the densitometric analysis of VEGF and NF-κB mRNA expression in rats from the four groups; (a) VEGF mRNA and (b) NF-κB mRNA. Data are represented as the mean ± standard deviation of one experiment consisting of three replicates. ** P<0.01 vs. sham operation and normal control groups; ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Expressing, Ligation, Real-time Polymerase Chain Reaction, Marker, Control, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Effect of M. suaveolens extract on the expression of VEGF and NF-κB65 protein in lung tissue. Groups of mice were challenged with cecal ligation and puncture and treated with M. suaveolens extract 24 h later. The expression of VEGF, NF-κβ65 and GAPDH was detected by western blotting using specific antibodies. GAPDH protein was used an internal control. (A) Representative western blot analysis demonstrated the levels of VEGF and NF-κB65 protein expression in rats from the four groups; (a) normal control group; (b) sham operation group; (c) (untreated) sepsis group and (d) treatment group. (B) Quantification of the blots by densitometric analysis of (a) VEGF and (b) NF-κB65 protein expression in rats from the four groups. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. ** P<0.01 vs. the sham operation group and normal control group; # P<0.05 vs . (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Expressing, Ligation, Western Blot, Control, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Effect of M. suaveolens extract on the protein expression of VEGF and NF-κB65 in rat lungs 24 h following cecal ligation and puncture-induced acute lung injury. Immunostaining was performed on lung sections following antigen retrieval using Retrievagen. (A) Representative immunostaining revealed VEGF and NF-κβ65-positive expression in rats from the four groups: (a–c) Expression of positive VEGF in the (a) sham operation group; (b) control group; (c) treatment group); (d–f) Expression of positive NF-κB65 in the (d) sham operation group; (e) (untreated) sepsis group; (f) treatment group (magnification, ×200). (B) Quantification of the images by densitometric analysis of (a) VEGF and (b) NF-κB-positive protein expression in rats from four groups. All values are expressed as the mean ± standard deviation. ** P<0.01 vs. the sham operation group; ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Expressing, Ligation, Immunostaining, Control, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Effect of M. suaveolens extract on plasma levels of VEGF, TNF-α, IL-6, IL-1β, IL-4 and IL-10 levels in plasma. Groups of mice were challenged with cecal ligation and puncture, and treated with M. suaveolens extract 24 h later. (A) VEGF, (B) TNF-α, (C) IL-6, (D) IL-1β, (E) IL-10 and (F) IL-4 levels in plasma were determined by ELISA. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. * P<0.05, ** P<0.01 vs. the sham operation group and normal control group; # P<0.05, ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; IL, interleukin.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Clinical Proteomics, Ligation, Enzyme-linked Immunosorbent Assay, Standard Deviation, Control

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Administration of M. suaveolens extract attenuated lipopolysaccharide-induced pulmonary inflammation. Groups of mice were challenged with cecal ligation and puncture, and treated with M. suaveolens extract 24 h later. (A) VEGF, (B) TNF-α, (C) IL-6, (D) IL-1β, (E) IL-10 and (F) IL-4 levels in bronchoalveolar lavage were determined by ELISA. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. ** P<0.01 vs. the sham operation group and normal control group; # P<0.05, ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; IL, interleukin.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Ligation, Enzyme-linked Immunosorbent Assay, Standard Deviation, Control

Journal: Molecular Medicine Reports

Article Title: Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis

doi: 10.3892/mmr.2015.3146

Figure Lengend Snippet: Administration of M. suaveolens extract reduces CLP-induced lung permeability. Rats were treated as indicated and (A) FITC-labeled albumin in the bronchoalveolar lavage fluid, (B) water content of lung tissue and (C) W/D lung weight ratio were determined 24 h following CLP challenge. Data are presented as the mean ± standard deviation of one experiment consisting of three replicates. * P<0.05, ** P<0.01 vs. the sham operation and normal control groups; ## P<0.01 vs. (untreated) sepsis group. VEGF, vascular endothelial growth factor; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; IL, interleukin; CLP, cecal ligation and puncture; W/D, wet/dry; FITC, fluorescein isothiocyanate.

Article Snippet: Primary antibodies used included rabbit anti-VEGF monoclonal antibody (1:400), rabbit anti-NF-κB65 monoclonal antibody (1:400) (Boster Biological Technology, Ltd) and mouse anti- GAPDH monoclonal antibody (1:400) (Santa Cruz Biotechnology, Inc).

Techniques: Permeability, Labeling, Standard Deviation, Control, Ligation